Zimmer Biomet (NYSE:ZBH) Issues FY 2025 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 8.100-8.300 for the period, compared to the consensus earnings per share estimate of 8.150. The company issued revenue guidance of $8.2 billion-$8.3 billion, compared to the consensus revenue estimate of $8.2 billion.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research note on Tuesday, October 7th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a research note on Thursday. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Finally, Raymond James Financial boosted their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $109.42.

Zimmer Biomet Trading Down 0.1%

NYSE:ZBH traded down $0.05 on Friday, hitting $88.46. 2,627,539 shares of the stock were exchanged, compared to its average volume of 1,937,229. The company’s 50-day moving average price is $100.50 and its 200 day moving average price is $97.54. Zimmer Biomet has a 52 week low of $85.33 and a 52 week high of $114.72. The stock has a market capitalization of $17.52 billion, a price-to-earnings ratio of 21.52, a P/E/G ratio of 2.29 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same quarter in the previous year, the business earned $1.74 EPS. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date was Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is owned by corporate insiders.

Institutional Trading of Zimmer Biomet

A number of large investors have recently bought and sold shares of ZBH. Headlands Technologies LLC acquired a new stake in Zimmer Biomet in the 2nd quarter valued at $37,000. Snowden Capital Advisors LLC grew its stake in Zimmer Biomet by 13.6% in the second quarter. Snowden Capital Advisors LLC now owns 5,635 shares of the medical equipment provider’s stock valued at $515,000 after purchasing an additional 674 shares in the last quarter. United Bank raised its stake in shares of Zimmer Biomet by 10.7% during the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after purchasing an additional 1,153 shares in the last quarter. Federated Hermes Inc. grew its stake in shares of Zimmer Biomet by 129.2% in the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after buying an additional 1,202 shares in the last quarter. Finally, State of Wyoming bought a new stake in Zimmer Biomet during the second quarter worth $124,000. 88.89% of the stock is owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.